Conor E. Steuer, MD | Winship Cancer ...

Dr. Conor Steuer

Claim this profile

Emory University Hospital Midtown

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
38 drugs studied

Area of expertise

1

Lung Cancer

Conor Steuer has run 9 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
KRAS positive
2

Non-Small Cell Lung Cancer

Conor Steuer has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
RET positive

Affiliated Hospitals

Image of trial facility.

Emory University Hospital Midtown

Image of trial facility.

Emory University Hospital/Winship Cancer Institute

Clinical Trials Conor Steuer is currently running

Image of trial facility.

Defactinib + Avutometinib + Nivolumab

for Lung Cancer

This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Defactinib and avutometinib belong to a class of drugs called kinase inhibitors. These drugs target kinase proteins found in tumor cells. Tumor cells need these proteins to survive and grow. By blocking these proteins, defactinib and avutometinib may cause tumors to stop growing or grow more slowly. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Giving defactinib and avutometinib in combination with nivolumab may kill more tumor cells in patients with anti-PD1 refractory LKB1-mutant advanced non-small cell lung cancer.

Recruiting

1 award

Phase 2

9 criteria

Image of trial facility.

MRX-2843 + Osimertinib

for Lung Cancer

This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Recruiting

1 award

Phase 1

20 criteria

More about Conor Steuer

Clinical Trial Related

1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Conor Steuer has experience with

  • Nivolumab
  • Pemetrexed
  • Durvalumab
  • Docetaxel
  • Pembrolizumab
  • Avutometinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Conor Steuer specialize in?

Is Conor Steuer currently recruiting for clinical trials?

Are there any treatments that Conor Steuer has studied deeply?

What is the best way to schedule an appointment with Conor Steuer?

What is the office address of Conor Steuer?

Is there any support for travel costs?